Abivax rises as investors cheer fully exercised upsized ADS offering

Abivax (ABVX) is up 7.7% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver is investor enthusiasm around Abivax’s large equity raise after underwriters fully exercised their option to buy additional ADSs, lifting total gross proceeds to about $920 million. While stock offerings often pressure shares, this deal appears to be viewed as a sign of strong demand and a meaningful boost to Abivax’s funding for late-stage development and potential U.S. commercialization of obefazimod.

Details:

Abivax said underwriters exercised in full their option to purchase 960,000 additional ADSs, increasing the total deal size to 7.36 million ADSs.

The company said gross proceeds from the offering rose to about $920 million, with estimated net proceeds of about $874.1 million.

Abivax said the funds are intended for potential U.S. commercialization of obefazimod, clinical development work in ulcerative colitis and Crohn’s disease, and general corporate purposes.

The company had already priced the main offering at $125 per ADS, above the previously announced $600 million size, suggesting the financing drew strong investor interest despite dilution.

Sources:

Abivax Investor Relations, SEC, MarketBeat

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

EARLY ACCESS

Receive ABVX Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$ABVX Hedge Fund Activity

We have seen 142 institutional investors add shares of $ABVX stock to their portfolio, and 108 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

POINT72 ASSET MANAGEMENT, L.P. removed 1,771,418 shares (-73.5%) from their portfolio in Q1 2026, for an estimated $197,247,394
MORGAN STANLEY removed 1,447,036 shares (-45.9%) from their portfolio in Q1 2026, for an estimated $161,127,458
DEUTSCHE BANK AG\ removed 764,899 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $85,171,503
PARADIGM BIOCAPITAL ADVISORS LP removed 645,000 shares (-45.5%) from their portfolio in Q1 2026, for an estimated $71,820,750
TCG CROSSOVER MANAGEMENT, LLC removed 630,511 shares (-8.9%) from their portfolio in Q1 2026, for an estimated $70,207,399
CORMORANT ASSET MANAGEMENT, LP removed 590,000 shares (-43.7%) from their portfolio in Q1 2026, for an estimated $65,696,500
ADAGE CAPITAL PARTNERS GP, L.L.C. removed 577,090 shares (-59.0%) from their portfolio in Q1 2026, for an estimated $64,258,971

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$ABVX Analyst Ratings

Wall Street analysts have issued reports on $ABVX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

BTIG issued a "Buy" rating on 06/30/2026

To track analyst ratings and price targets for $ABVX, check out Quiver Quantitative's $ABVX forecast page.

$ABVX Price Targets

Multiple analysts have issued price targets for $ABVX recently. We have seen 8 analysts offer price targets for $ABVX in the last 6 months, with a median target of $151.5.

Here are some recent targets:

Gregory Renza from Truist Securities set a target price of $155.0 on 07/02/2026
Jason N. Butler from Citizens set a target price of $187.0 on 07/01/2026
Julian Harrison from BTIG set a target price of $175.0 on 06/30/2026
David Nierengarten from Wedbush set a target price of $110.0 on 06/30/2026
Thomas Smith from Leerink Partners set a target price of $148.0 on 06/30/2026
Faisal Khurshid from Jefferies set a target price of $158.0 on 06/30/2026
Judah Frommer from Morgan Stanley set a target price of $132.0 on 06/02/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.